Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes.
Methylglyoxal (MG) may be an important cause of diabetic complications. Its primary source is dihydroxyacetone phosphate (DHAP) whose levels are partially controlled by glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Using a human red blood cell (RBC) culture, we examined the effect of modifying GAPDH activity on MG production. With the inhibitor koningic acid (KA), we showed a linear, concentration-dependent GAPDH inhibition, with 5 microM KA leading to a 79% reduction of GAPDH activity and a sixfold increase in MG. Changes in redox state produced by elevated pH also resulted in a 2.4-fold increase in MG production at pH 7.5 and a 13.4-fold increase at pH 7.8. We found substantial inter-individual variation in DHAP and MG levels and an inverse relationship between GAPDH activity and MG production (R=0.57, P=0.005) in type 2 diabetes. A similar relationship between GAPDH activity and MG was observed in vivo in type 1 diabetes (R=0.29, P=0.0018). Widely varying rates of progression of diabetic complications are seen among individuals. We postulate that modification of GAPDH by environmental factors or genetic dysregulation and the resultant differences in MG production could at least partially account for this observation.
Beisswenger
Paul J
PJ
Department of Medicine, Endocrine-Metabolism Division, Dartmouth Medical School, Hanover, NH 03755, USA. paul.j.beisswenger@hitchcock.org
Howell
Scott K
SK
Smith
Kenneth
K
Szwergold
Benjamin S
BS
D000328:Adult; D002478:Cells, Cultured; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D005260:Female; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D011765:Pyruvaldehyde / Q000097:blood / Q000378:metabolism*; D012717:Sesquiterpenes / Q000627:therapeutic use*
D004791:Enzyme Inhibitors; D012717:Sesquiterpenes; C027285:heptelidic acid; D011765:Pyruvaldehyde; D005987:Glyceraldehyde-3-Phosphate Dehydrogenases